Search results
Results from the WOW.Com Content Network
Selective serotonin reuptake inhibitors (SSRIs) are a class of drugs that are typically used as antidepressants in the treatment of major depressive disorder, anxiety disorders, and other psychological conditions. SSRIs increase the extracellular level of the neurotransmitter serotonin by limiting its reabsorption (reuptake) into the ...
Selective serotonin reuptake inhibitors (SSRIs) are believed to increase the extracellular level of the neurotransmitter serotonin by limiting its reabsorption into the presynaptic cell, increasing the level of serotonin in the synaptic cleft available to bind to the postsynaptic receptor.
Selective serotonin reuptake inhibitors (SSRIs) selectively inhibit the reuptake of serotonin and are a widely used group of antidepressants. [31] With increased receptor selectivity compared to TCAs, undesired effects such as poor tolerability are avoided. [29] Serotonin is synthesized from an amino acid called L-tryptophan.
Other Treatment Options for PTSD Beyond psychotherapy and more traditional medications, experimental and alternative approaches are emerging to potentially treat PTSD. These include ketamine ...
Bipolar disorder is a long-term mood disorder characterized by major fluctuations in mood — both high and low — that can impact daily functioning and behavior. Bipolar Disorder: 4 Types & What ...
Many antidepressants reduce depression by increasing norepinephrine and/or serotonin levels. ... both men and women — found that blood magnesium levels were inversely associated with fat mass ...
Serotonin. A serotonin reuptake inhibitor (SRI) is a type of drug which acts as a reuptake inhibitor of the neurotransmitter serotonin (5-hydroxytryptamine, or 5-HT) by blocking the action of the serotonin transporter (SERT). This in turn leads to increased extracellular concentrations of serotonin and, therefore, an increase in serotonergic ...
NHS figures show that the number of people in England taking antidepressants continues to rise, with 8.3m patients receiving them in 2021/22.